TriangleNCT01716806 · OUTCOME
Overall Survival (Parts E and F Only)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 44 months
What was measured
Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.
Analysis population: All subjects who received at least one dose of study drug
Groups in this outcome
Part E
BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.
Part F
BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.
| Group | Source count |
|---|---|
| Part E | 30 |
| Part F | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part E | 31.8 | Not reported | 14.8 | NA | Follow-up duration too short relative to event accumulation to estimate upper limit. |
| Part F | 12.6 | Not reported | 0.5 | NA | Follow-up duration too short relative to event accumulation to estimate upper limit. |
Complete source fields
- classes
- categories
- measurements
- comment
- Follow-up duration too short relative to event accumulation to estimate upper limit.
- group Id
- OG000
- lower Limit
- 14.8
- upper Limit
- NA
- value
- 31.8
- comment
- Follow-up duration too short relative to event accumulation to estimate upper limit.
- group Id
- OG001
- lower Limit
- 0.5
- upper Limit
- NA
- value
- 12.6
- denoms
- counts
- group Id
- OG000
- value
- 30
- group Id
- OG001
- value
- 7
- units
- Participants
- description
- Overall survival (OS) per investigator was defined as the time from date of enrollment to date of death due to any cause.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- BV as frontline monotherapy in patients with cHL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.
- id
- OG000
- title
- Part E
- description
- BV as frontline monotherapy in patients with CD30-expressing PTCL who were unsuitable or unfit for combination chemotherapy. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.
- id
- OG001
- title
- Part F
- param Type
- MEDIAN
- population Description
- All subjects who received at least one dose of study drug
- reporting Status
- POSTED
- time Frame
- Up to 44 months
- title
- Overall Survival (Parts E and F Only)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice